Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Melanoma 16Carcinoma, Renal Cell 13Carcinoma, Non-Small-Cell Lung 7Neoplasm Metastasis 6Clear-cell metastatic renal cell carcinoma 6Lung Neoplasms 5Prostatic Neoplasms 4Myelodysplastic Syndromes 4Brain Neoplasms 4Urinary Bladder Neoplasms 3Urethral Neoplasms 3Ovarian Neoplasms 3Leukemia, Myeloid, Acute 3Histiocytoma, Malignant Fibrous 3Carcinoma, Transitional Cell 3Carcinoma, Basal Cell 3Urogenital Neoplasms 2Ureteral Neoplasms 2Triple Negative Breast Neoplasms 2Thyroid Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Rectal Neoplasms 2Penile Neoplasms 2Nasopharyngeal Carcinoma 2Meningioma 2Lymphoma 2Hematologic Neoplasms 2Glioblastoma 2Carcinoma, Merkel Cell 2

Interventions

Temozolomide 15Radiotherapy 10Radiation 8Magnetic Resonance Spectroscopy 7pembrolizumab 5Specimen Handling 5Ipilimumab 3atezolizumab 2Photons 2Nivolumab 2Biopsy 2veliparib 1selinexor 1sargramostim 1plerixafor 1peposertib 1pazopanib 1navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1montanide ISA 51 1liposomal doxorubicin 1gosha-jinki-gan 1fluorodopa F 18 1ferric pyrophosphate 1efineptakin alfa 1cemiplimab 1cabozantinib 1balstilimab 1abexinostat 1X-Rays 1Vorinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gliosarcoma × CTLA-4 Antigen × 1 year × Clear all
NCT04396860 2026-04-22

Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

National Cancer Institute (NCI)

Phase 2/3 Completed
159 enrolled 17 charts
Sarcoma

Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡